Home > Insider Trading > Filing (0001209191-19-043061)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1759425	Mirum Pharmaceuticals Inc.	MIRM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1237289	D Scott Sandell	1954 Greenspring Drive Suite 600 Timonium MD 21093		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-22	3,736,243	$0.00	3,736,243	No	4	C	Indirect	See Note 2
Common Stock	Acquisiton	2019-07-22	450,000	$15.00	4,186,243	No	4	P	Indirect	See Note 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Note 2
No	4	P	Indirect	See Note 2

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-07-22	29,889,945	$0.00	3,736,243	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125shares of the Issuer's common stock. The shares have no expiration date.
The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEAPartners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial ownerof the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, asamended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest.
The shares were purchased in the Issuer's initial public offering.